Amrutanjan Health Care Limited (AMRUTANJAN)

Loading page…

Amrutanjan Health Care Limited (AMRUTANJAN) · mywealthgrid

About

Amrutanjan Health Care Limited operates in the pharmaceuticals sector within the healthcare industry. With a market capitalization of ₹1,433.58 Cr, the company generates quarterly revenue in the ₹100–150 Cr range and has maintained regular dividend distributions, indicating operational cash generation.

Face value: ₹1

Market cap

₹1,483 Cr

P/E

27.5×

P/B

4.0×

Dividend yield

1.5%

ROE

16.6%

ROCE

24.2%

Debt / equity

OPM

15.1%

EPS (TTM)

₹18.7

Book value

₹128.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin volatility of 15 percentage points (4.24% to 19.02% across recent quarters) indicates operational inconsistency or seasonal factors; verify root cause and whether strong margins can be sustained.
Recent quarter deterioration: Jun 2026 revenue ₹103 Cr with OPM 6.06% and EPS ₹1.51, down sharply from Mar 2026 EPS ₹5.60; verify if this is cyclical or signal of trend shift.
Valuation (PE 26.56) appears stretched given earnings volatility (EPS ranges from ₹1.51 to ₹6.73); verify normalized earnings power.
Modest year-on-year growth: Jun 2025 to Jun 2026 revenue grew ~10% (₹94 Cr to ₹103 Cr); verify if growth can accelerate.

Generated analysis · source review pending

Growth drivers

Margin expansion potential: Dec 2024 and Mar 2026 achieved 17–19% OPM while Jun 2026 sits at 6.06%; normalizing weak quarters to strong-quarter levels would significantly expand EPS without revenue growth.
Consistent cash generation: Five dividend payments over 18 months (Feb 2026, Nov 2025, Sep 2025, Feb 2025, Nov 2024) demonstrate profitability and shareholder returns; verify if capital allocation will shift to growth investment.
Organic revenue growth from ₹94 Cr (Jun 2025) to ₹103 Cr (Jun 2026) shows mid-single-digit expansion; acceleration depends on market opportunity—verify product focus and therapeutic positioning.
Zero debt (D/E 0) provides financial flexibility for growth capex or acquisitions; verify if balance sheet will be deployed for expansion.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹513.2+1.6%1Y

Quick read

rule-based

Pros

+High return on capital employed of 22.3%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 434.7×
+Dividend payout of 40.2% of profit

Cons

−Profit declined 1.1% a year over the last 5 years
−Modest revenue growth of 8.6% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

52/100

Business quality: 69
Growth: 33
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	183	70	70	253	261	333	406	380	421	452	503
COGS	—	30	30	119	117	140	180	182	212	223	244
Gross profit	—	39	39	134	144	193	225	198	209	229	258
	155	32	32	103	114	118	146	153	158	170	183
	28	7	7	31	31	75	79	44	51	58	76
OPM %	15.2%	10.1%	10.1%	12.4%	11.8%	22.5%	19.6%	11.7%	12.2%	12.9%	15.1%
Depreciation	—	0	0	3	4	4	4	5	6	7	6
Interest	0	0	0	0	0	1	0	0	0	0	0
	6	1	1	7	8	11	15	15	17	18	9
Profit before tax	35	7	7	35	34	82	91	54	62	69	78
Tax	12	4	4	10	9	21	23	14	17	18	20
Tax %	35.1%	63.1%	63.1%	29.3%	27.2%	25.3%	25.8%	25.7%	27.4%	26.5%	25.6%
	22	3	3	25	25	61	67	40	45	51	58
PAT margin %	12.2%	3.8%	3.8%	9.7%	9.6%	18.4%	16.6%	10.5%	10.7%	11.3%	11.5%
EPS (₹)	15.3	1.8	1.8	8.4	8.6	20.9	23.1	13.7	15.6	17.6	20
EPS adjusted (₹)	—	—	—	—	—	21	23	13.6	15.6	17.6	20
	25.1%	213.9%	169.4%	25.7%	24.5%	20.1%	20%	33.7%	29.6%	26.2%	24.5%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3
Reserves	213	262	288	286	324	367
	0	0	0	0	0	0
	59	85	71	78	95	139
Total equity & liabilities	274	350	362	367	421	509
	23	28	49	50	49	51
CWIP	0	16	1	2	16	105
Investments	18	13	5	0	0	3
	233	292	307	315	356	349
Total assets	274	350	362	367	421	509

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
OTC Products	328.32	83.44	78.97	57.26	21.71	384.34
Women's Hygiene & Personal Care	139.91	-2.72

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	53.1%	55.2%	57.9%	55.5%	52.1%	49.7%	50.6%	51.4%
EBITDA margin %	12.4%	11.8%	22.5%	19.6%	11.7%	12.2%	12.9%	15.1%
EBIT margin %	11.1%	10.1%	21.4%	18.6%	10.3%	10.7%	11.4%	13.8%
PAT margin %	9.7%	9.6%	18.4%	16.6%	10.5%	10.7%	11.3%	11.5%
Working capital
Receivable days	—	—	19	34	32	41	45	44
Inventory days	—	—	45	53	58	50	45	56
Payable days	—	—	106	122	95	96	113	106
NWC days	—	—	-41	-35	-6	-5	-23	-6
Leverage
Current ratio	—	—	4.28	3.55	4.12	4.23	3.44	2.31
Debt to EBITDA	—	—	0	0	0	0	0	0
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	440.6	157.6	164.8	189.7	671.6	388.1	315.3	434.7
Asset turnover	—	—	1.21	1.16	1.05	1.15	1.07	0.99
Return ratios
Return on assets %	—	—	22.3%	19.2%	11%	12.3%	12.1%	11.4%
Return on capital employed %	—	—	37.1%	36.8%	18.8%	20.8%	21.9%	24.2%
Return on equity %	—	—	28.4%	25.3%	13.7%	15.6%	15.6%	15.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	50.59%	50.59%	50.59%	50.59%	46.52%	46.52%	46.52%	46.52%	46.52%	46.52%	46.52%	46.52%
	0.75%	0.8%	1.38%	1.55%	2.34%	2.3%	2.3%	2.41%	2.38%	2.27%	2.17%	2.44%
	7.1%	7.24%	7.29%	7.32%	10.6%	11.12%	11.41%	12.7%	12.9%	13%	12.66%	12.28%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	41.38%	41.19%	40.67%	40.47%	40.5%	40.02%	39.73%	38.33%	38.17%	38.18%	38.62%	38.73%
No. of shareholders	—	—	—	—	—	—	—	—	47,954	46,675	45,805	45,135

Promoter holding down 4.07 percentage points since Sep 2023.

8 deals · 30 Jun 2023 – 20 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
20 Aug 2026	PARI WASHINGTON INDIA MASTER FUND, LTD.	Bulk	BSE	Buy	5,83,481	₹500.00	₹29.17 Cr
20 Aug 2026	DSP MUTUAL FUND	Bulk	BSE	Sell	5,00,000	₹500.01	₹25.00 Cr
13 Jan 2025	SUNDARAM MUTUAL FUND	Bulk	NSE	Sell	2,13,500	₹700.00	₹14.95 Cr
27 Sept 2024	NAGESWARAMMA PRIVATE TRUST	Bulk	BSE	Sell	3,40,275	₹745.29	₹25.36 Cr
26 Sept 2024	NAGESWARAMMA PRIVATE TRUST	Bulk	NSE	Sell	8,32,725	₹760.08	₹63.29 Cr
26 Sept 2024	ICICI PRUDENTIAL MUTUAL FUND	Bulk	NSE	Buy	6,50,000	₹760.00	₹49.40 Cr
30 Jun 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	1,91,539	₹737.86	₹14.13 Cr
30 Jun 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	1,91,539	₹737.21	₹14.12 Cr

1–8 of 8

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. SAMBHUPRASAD SIVALENKAExecutive Director-Chairperson-MD
N SwaminathanChief Financial Officer
Mr. S MURALIDHARANNon-Executive - Independent Director
Mrs. MEENALOCHANI RAGHUNATHANNon-Executive - Independent Director
Mrs. RAMAA P ARIKIREVULANon-Executive - Non Independent Director
Mr. NAGARAJ VISWANATHANNon-Executive - Independent Director
Mr. RAMASWAMI KRISHNANNon-Executive - Independent Director
Mr. Gagan Preet SinghCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 2 fund houses

Held by these funds

2.57%

of the company's equity

All mutual funds

5.82%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

3 schemes · 2 fund houses

		Shares
FMCG Fund	ICICI Prudential Mutual Fund	6.6 L	33.64	2.16%	2.285%	-0
Quant Fund	ICICI Prudential Mutual Fund	46,122	2.35	1.39%	0.16%	-0
Small Cap Fund	DSP Mutual Fund	35,314	1.8	0.01%	0.122%	-7.81 L

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

7 announcementsExport CSV

28 Aug 2026, 1:51 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	53.1%	55.2%	57.9%	55.5%	52.1%	49.7%	50.6%	51.4%
EBITDA margin %	12.4%	11.8%	22.5%	19.6%	11.7%	12.2%	12.9%	15.1%
EBIT margin %	11.1%	10.1%	21.4%	18.6%	10.3%	10.7%	11.4%	13.8%
PAT margin %	9.7%	9.6%	18.4%	16.6%	10.5%	10.7%	11.3%	11.5%
Working capital
Receivable days	—	—	19	34	32	41	45	44
Inventory days	—	—	45	53	58	50	45	56
Payable days	—	—	106	122	95	96	113	106
NWC days	—	—	-41	-35	-6	-5	-23	-6
Leverage
Current ratio	—	—	4.28	3.55	4.12	4.23	3.44	2.31
Debt to EBITDA	—	—	0	0	0	0	0	0
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	440.6	157.6	164.8	189.7	671.6	388.1	315.3	434.7
Asset turnover	—	—	1.21	1.16	1.05	1.15	1.07	0.99
Return ratios
Return on assets %	—	—	22.3%	19.2%	11%	12.3%	12.1%	11.4%
Return on capital employed %	—	—	37.1%	36.8%	18.8%	20.8%	21.9%	24.2%
Return on equity %	—	—	28.4%	25.3%	13.7%	15.6%	15.6%	15.6%

49

Final dividend11 Sept 2026 · ex-date₹2.9
Interim dividend6 Feb 2026 · ex-date₹1
Interim dividend18 Nov 2025 · ex-date₹1
Final dividend16 Sept 2025 · ex-date₹2.6
Interim dividend18 Feb 2025 · ex-date₹1
Interim dividend22 Nov 2024 · ex-date₹1
Final dividend13 Sept 2024 · ex-date₹2.6
Interim dividend20 Feb 2024 · ex-date₹1
Interim dividend23 Nov 2023 · ex-date₹1
Final dividend14 Sept 2023 · ex-date₹2.6
Interim dividend24 Feb 2023 · ex-date₹1
Interim dividend14 Nov 2022 · ex-date₹1
Final dividend14 Sept 2022 · ex-date₹2.6
Interim dividend18 Feb 2022 · ex-date₹1
Interim dividend16 Nov 2021 · ex-date₹1
Final dividend15 Sept 2021 · ex-date₹2.6
Interim dividend17 Feb 2021 · ex-date₹0.8
Interim dividend19 Nov 2020 · ex-date₹0.8
Interim dividend18 Feb 2020 · ex-date₹1.55
Interim dividend15 Nov 2019 · ex-date₹0.55
Final dividend17 Sept 2019 · ex-date₹1.05
Interim dividend20 Feb 2019 · ex-date₹0.55
Interim dividend12 Nov 2018 · ex-date₹0.55
Final dividend7 Sept 2018 · ex-date₹0.85
Interim dividend22 Feb 2018 · ex-date₹1.1
Interim dividend16 Nov 2017 · ex-date₹1.1
Final dividend13 Sept 2017 · ex-date₹1.65
Interim dividend16 Feb 2017 · ex-date₹1.1
Interim dividend17 Nov 2016 · ex-date₹1.1
Interim dividend18 Mar 2016 · ex-date₹2.65
Interim dividend17 Feb 2016 · ex-date₹1.2
Final dividend10 Sept 2015 · ex-date₹2.4
Interim dividend13 Feb 2015 · ex-date₹1.1
Final dividend17 Sept 2014 · ex-date₹2.2
Interim dividend17 Feb 2014 · ex-date₹1
Final dividend2 Aug 2013 · ex-date₹2
Interim dividend21 Feb 2013 · ex-date₹1
Final dividend20 Sept 2012 · ex-date₹10
Interim dividend23 Feb 2012 · ex-date₹5
Final dividend12 Sept 2011 · ex-date₹10
Interim dividend21 Feb 2011 · ex-date₹5
Final dividend13 Aug 2010 · ex-date₹10
Interim dividend9 Feb 2010 · ex-date₹5
Dividend dividend16 Sept 2009 · ex-date₹12
Interim dividend4 Feb 2009 · ex-date₹5
Final dividend8 Sept 2008 · ex-date₹3
Interim dividend28 Jul 2008 · ex-date₹40
Interim dividend5 Feb 2008 · ex-date₹4
Final dividend3 Aug 2007 · ex-date₹2

1

Board meeting to consider results11 Aug 2026

2

Face value ₹2 → ₹113 Apr 2018 · ex-date
Face value ₹10 → ₹225 Oct 2012 · ex-date

Date	Category	Subject	Filing
28 Aug 2026, 1:51 pm	Others Business Responsibility and Sustainability Reporting (BRSR)	Business Responsibility and Sustainability Reporting (BRSR)	PDF
28 Aug 2026, 1:46 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
12 Aug 2026, 8:39 pm	Company Update General	Investor Presentation For The Quarter Ended 30Th June 2026	PDF
11 Aug 2026, 6:34 pm	Corp. Action Record Date	Record Date For The Final Dividend And AGM	PDF
11 Aug 2026, 6:24 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Financial Results And Outcome Of The Board Meeting	PDF
1 Aug 2026, 7:44 pm	Company Update General	Intimation Of Under Regulation 30 Read With Clause 20 Of Para A Of Part A Of Schedule Ill Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	PDF
8 Jul 2026, 10:21 am	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	17	53	19	28	51	36
	-15	-36	-2	19	-31	-21
	-6	-18	-14	-48	-13	-14
Net cash flow	-4	-1	3	-1	6	1
Free cash flow	15	30	10	21	15	-19
CFO / Operating profit %	22.7%	66.9%	43.3%	54.5%	87.4%	47.5%

Amrutanjan Health Care Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Segment results

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

49

1

2

Segment results

Compounded sales growth

Compounded profit growth

Return on equity

BEVARAGES · revenue

Amrutanjan Health Care Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Dividends49

Board meetings1

Stock splits2

Profit & loss

Balance sheet

Segment results

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

BEVARAGES · revenue

49

1

2